Christine McGinley, DO
Family Medicine · Little River, SCNPI 1558314914
Payments from drug & device makers
Across 67 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$398
- Amarin Pharma, Inc.$205
- AbbVie$189
- GSK$163
- Novo Nordisk$133
- Gilead$121
- plus $642 from 15 others
What the payments were for
- Food & beverage$1,845100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 14 | $398 |
| Amarin Pharma, Inc. | 6 | $205 |
| AbbVie | 8 | $189 |
| GSK | 4 | $163 |
| Novo Nordisk | 5 | $133 |
| Gilead | 1 | $121 |
| Inari Medical, Inc. | 1 | $119 |
| Merck | 3 | $116 |
| Astellas Pharma US Inc | 5 | $82 |
| Indivior Inc. | 4 | $66 |
| Pfizer | 3 | $47 |
| Abbott | 3 | $47 |
| Braeburn Inc. | 2 | $34 |
| Bayer | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,851 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 138 | $528,759 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 43 | $166,715 |
| OzempicSemaglutide | 104 | $126,591 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $91,839 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $89,023 |
| MounjaroTirzepatide | 75 | $87,866 |
| DovatoDolutegravir Sodium/Lamivudine | 27 | $81,397 |
| EliquisApixaban | 65 | $71,901 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 55 | $66,748 |
| JardianceEmpagliflozin | 59 | $63,326 |
| JanuviaSitagliptin Phosphate | 41 | $45,872 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $39,641 |
| IsentressRaltegravir Potassium | 21 | $37,377 |
| FarxigaDapagliflozin Propanediol | 26 | $27,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $27,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $121 | $657,424182 claims |
| Viiv Healthcare CompanyTriumeq, Dovato | $398 | $248,11270 claims |
| MerckJanumet Xr, Januvia, Isentress | $116 | $149,997117 claims |
| Novo NordiskOzempic | $133 | $126,591104 claims |
| PfizerEliquis | $47 | $71,90165 claims |
| Boehringer IngelheimJardiance | $19 | $63,32659 claims |
| GSKTrelegy Ellipta | $163 | $27,47237 claims |
| AbbVieSynthroid | $189 | $1,97431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Little River
- Stephen GrubbLittle River$3.4M
- Tom ChristensenLittle River$3.1M
- Darron MolterLittle River$36K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.